The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:
----------
Octopus Titan VCT PLC - London-based venture capital trust - NAV per share at December 31 76.9 pence, down from 105.7p a year ago, reflecting ‘the difficult global macro environment we have faced in the last year and follows a record year in 2021’. NAV total return negative 23%, swinging from positive 20.3% the year prior. Declares dividend of 3.0p per share, unchanged from 2021. Says it is well-placed to navigate short-term uncertainty, and is confident in its long-term outlook.
----------
Next 15 Group PLC - London-based digital marketing firm - Revenue for 2022 £720.5 million, up 53% from £470.1 million in 2021, boosted by acquisitions. Pretax profit is £10.1 million, swinging from a pretax loss of £80.1 million a year ago. Declares final dividend of 10.1p per share, an increase of 20% on 2021, bringing the total dividend to 14.6p per share, up from 8.4p. Says it is confident in meeting full-year expectations, having seen a strong start in 2023. Chief Executive Tim Dyson says: ‘Looking ahead, our positive trading has continued into our new financial year with good levels of activity across all four parts of the business. We have continued to see strong levels of spend from all of our major customers. In addition, our work with the public sector has remained strong and is anticipated to grow in the current year. We therefore expect our results for the full year to be in line with management expectations.’
----------
Avacta Group PLC - life sciences company, developing targeted oncology drugs and diagnostics - Pretax loss in 2022 is £41.6 million, widening from £29.2 million a year ago. Revenue totals £9.7 million, tripling from £2.9 million. Loss per share widens to 15.35p, from 10.55p in 2021. Declares no dividend, unchanged from a year ago. Says near-term value driver for the company is the phase 1 clinical data from its AVA6000 study, which looks ‘very promising’. Chief Executive Alastair Smith comments: ‘The progress made during 2022 has positioned Avacta for further strong growth during 2023.’
----------
hVIVO PLC - London-based specialist contract research organisation providing testing for infectious and respiratory vaccine - Revenue for 2022 £50.7 million, up 30% from £39.0 million in 2021. Says growth was driven by the expansion of the human challenge market and the increasing utility of challenge study data. Pretax loss is £365,000, swinging from pretax profit of £277,000 a year ago. Basic loss per share widens to 0.12p, from a loss per share of 0.01p in 2021. Declares special dividend of 0.45p per share. ‘2022 marked a transformative year for hVIVO, as we achieved record financial and operational performance, providing strong validation of our sustainable growth model. With exceptional financial strength, and an impressive orderbook, we are proud to have full visibility of 2023 revenue guidance with strong visibility into H1 2024,’ comments Chief Executive Yamin Khan.
----------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
